Diphtheria Market Report 2026

The diphtheria market size has grown strongly in recent years. It will grow from $9.39 billion in 2025 to $9.96 billion in 2026 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to historical disease outbreaks, limited vaccination coverage, poor sanitation conditions, lack of early diagnosis, uneven healthcare access.

The diphtheria market size is expected to see strong growth in the next few years. It will grow to $13.05 billion in 2030 at a compound annual growth rate (CAGR) of 7%. The growth in the forecast period can be attributed to global immunization campaigns, improved diagnostic access, public health funding, disease surveillance digitization, outbreak preparedness programs. Major trends in the forecast period include continued demand for vaccination and immunization programs, increased focus on early diagnosis and surveillance, growing use of antibiotic and antitoxin therapies, expansion of public health awareness initiatives, strengthening of infectious disease monitoring systems.

The increasing prevalence of bacterial infections is expected to drive the growth of the diphtheria market in the coming years. Bacterial infections are illnesses or conditions caused by the growth of bacteria or the toxins they release after invading the body. Diphtheria is a severe bacterial infection caused by toxin-producing strains that weaken the immune system and promote the spread of *Corynebacterium diphtheriae*. For instance, in March 2024, according to the Centers for Disease Control and Prevention, a US-based government agency, tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023, an increase of 1,295 cases. Therefore, the growing prevalence of bacterial infections is contributing to the expansion of the diphtheria market.

Major companies operating in the diphtheria market are increasingly focusing on advanced formulation approaches such as thermostabilisation technologies to improve distribution efficiency, enhance temperature resistance, and reduce reliance on cold-chain logistics. Thermostabilisation technologies are formulation methods designed to protect vaccine antigens from heat-related degradation, enabling features such as stability at room temperature, lower wastage, and improved delivery in remote areas. For instance, in April 2025, Stablepharma Ltd, a UK-based biotechnology company, entered Phase 1 clinical trials with SPVX02, a refrigerator-free tetanus-diphtheria vaccine developed to retain potency after exposure to temperature variations ranging from -20°C to +40°C and provide up to 18 months of shelf life at room temperature. SPVX02 enhances vaccine stability, strengthens supply-chain reliability, and improves access in regions with limited infrastructure.

In June 2025, BioNet, a Thailand-based vaccine biotechnology company, partnered with PT Bio Farma (Persero) to expand access to a next-generation Tdap vaccine across ASEAN markets. Through this collaboration, BioNet and Bio Farma aim to combine BioNet’s recombinant pertussis technology with Bio Farma’s large-scale manufacturing expertise to increase regional immunisation coverage, improve vaccine availability for priority population groups, and support long-term vaccine supply self-sufficiency in Southeast Asia. PT Bio Farma (Persero) is an Indonesia-based state-owned vaccine manufacturer with a broad portfolio of routine immunisation vaccines.

Major companies operating in the diphtheria market are Sanofi Pasteur, GlaxoSmithKline plc, Serum Institute of India Pvt Ltd, Biological E Limited, Bharat Biotech International Limited, Panacea Biotec Ltd, Mitsubishi Tanabe Pharma Corporation, KM Biologics (Meiji Holdings), AJ Vaccines, Bionet‑Asia, Wuhan Institute of Biological Products, Walvax Biotechnology Co Ltd, Chengdu Institute of Biological Products Co Ltd, Minhai Biotechnology, Bio Farma Persero, Indian Immunologicals Ltd, LG Chem Ltd, Astellas Pharma Inc, Takeda Pharmaceutical Company Limited, MassBiologics, Shanghai Institute of Biological Products Co Ltd, Changchun Institute of Biological Products Co Ltd, Hualan Biological Engineering Inc, Valneva SE, Pasteur Institute of India, Beijing Tiantan Biological Products Co Ltd, Chongqing Zhifei Biological Products Co Ltd, Shenzhen Kangtai Biological Products Co Ltd.

Asia-Pacific was the largest region in the diphtheria market in 2025. The regions covered in the diphtheria market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the diphtheria market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the diphtheria market by increasing costs of imported vaccines, antibiotics, and diagnostic kits. Low- and middle-income regions are most affected due to reliance on imported supplies, while developed regions face higher procurement costs. These tariffs increase treatment expenses. However, they also encourage domestic vaccine production and regional pharmaceutical manufacturing.

The diphtheria market research report is one of a series of new reports that provides diphtheria market statistics, including diphtheria industry global market size, regional shares, competitors with a diphtheria market share, detailed diphtheria market segments, market trends and opportunities, and any further data you may need to thrive in the diphtheria industry. This diphtheria market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Diphtheria is a bacterial disease caused by strains of *Corynebacterium diphtheriae* that produce a toxin primarily affecting the mucous membranes of the throat and nose, and in severe cases, other parts of the body. It is characterized by symptoms such as throat pain, weakness, fever, swollen neck glands, breathing difficulties caused by tissue blockage in the nose and throat, and difficulty swallowing.

The main infection types associated with diphtheria include respiratory diphtheria, skin diphtheria, and others. Diphtheria is a serious bacterial infection that can affect the tonsils, nose, throat, and or skin due to toxin-producing *Corynebacterium diphtheriae*. Diagnosis involves methods such as physical examination, throat culture, and other tests, and treatment includes antibiotics, antitoxin therapy, and other supportive measures. These treatments are distributed through hospital pharmacies, online pharmacies, and retail pharmacies and are used in hospitals, homecare settings, specialty clinics, and other healthcare facilities.

The diphtheria market consists of revenues earned by entities by providing services such as consultation, diagnosis and treatment. The market value includes the value of related goods sold by the service provider or included within the service offering. The diphtheria market also includes the sales of medications such as vaccines, antibiotics and antitoxins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.